AdoraPet Biosciences is a company.
Key people at AdoraPet Biosciences.
AdoraPet Biosciences was founded by Richard Chin (Co-Founder and Chairman of the Board of Directors).
Key people at AdoraPet Biosciences.
AdoraPet Biosciences was founded by Richard Chin (Co-Founder and Chairman of the Board of Directors).
AdoraPet Biosciences is a biotechnology startup based in San Mateo, California, developing CRISPR-based gene editing technologies to create healthier, longer-living dogs and cats free from cancer and allergies.[2][3][5] The company targets pet owners by editing genes at the egg stage or via insertion to eliminate disease-causing mutations, addressing common pet health issues that shorten lifespans and cause owner allergies.[1][2][4] It solves the problem of pet mortality from cancer (affecting ~50% of dogs and 90% of cats over age 10) and allergies, aiming to extend pet lifespans by 30-50% while boosting owner-pet bonding time.[3][4]
Launched around 2022, AdoraPet sought $5 million via crowdfunding under Regulation CF, as filed with the SEC, indicating early-stage growth momentum through equity crowdfunding on platforms like DealMaker.[3][4][5]
AdoraPet Biosciences emerged in late 2022 from a collaboration between genomics pioneer George Church—a Harvard professor known for advancing CRISPR—and executives from KindredBio, a pet biotech acquired by Elanco.[2][1] Key figures include a serial biotech entrepreneur who founded KindredBio (NASDAQ:KIN), served as Genentech's Head of Clinical Research, and led other ventures like Infinita Life Science (anti-aging therapies) and Bio Usawa (affordable cancer therapies); he now acts as founder and board member of AdoraPet.[1]
The idea stemmed from Church's expertise in genome engineering and the former KindredBio team's pet therapeutics experience, pivoting to preventive gene editing for companion animals.[2] A pivotal moment was their December 2022 SEC Form C filing to raise funds via crowdfunding, marking formal launch and early investor traction amid rising interest in designer pets.[3][5]
AdoraPet rides the CRISPR pet editing wave, fueled by falling gene-editing costs and surging $100B+ global pet industry spending (projected to hit $150B by 2030), where owners treat pets like family amid aging populations.[2][3] Timing aligns with regulatory progress (e.g., FDA's gene-edited animal approvals) and consumer demand for "designer" hypoallergenic/longevity pets, mirroring human longevity biotech trends.[1][2]
Market forces like post-pandemic pet adoptions (up 20%) and vet shortages favor preventive tech over reactive care.[3] AdoraPet influences the ecosystem by normalizing CRISPR in consumer biotech, potentially accelerating vet genomics startups and ethical debates on animal editing.[2][4]
AdoraPet's crowdfunding success signals strong early validation; next steps likely include prototype litters, FDA veterinary biologics clearance, and partnerships with breeders/vets by 2026-2027.[3][5] Trends like AI-optimized CRISPR (e.g., Church's influence) and pet humanization will propel growth, with potential $1B+ valuation if first allergy-free breeds launch.[2]
Influence may evolve from niche innovator to pet health leader, akin to KindredBio's path, reshaping how biotech extends companion animal lifespans and owner joy—echoing its mission for healthier, cancer-free pets.[1][4]
